Doppler echocardiography is used to screen for HIV-related pulmonary arterial hypertension (HRPAH). We studied patients with HIV infection to determine the accuracy of Doppler echocardiography-estimated pulmonary artery systolic pressure (PASP) compared with PASP measured during right heart catheterization. Doppler echocardiography-estimated PASP was inaccurate in 19.7% of cases. Using Doppler echocardiography-estimated PASP, one in three patients with HRPAH was missed. Doppler echocardiography estimates of PASP are not accurate in patients with HIV.
Pulmonary arterial hypertension (PAH) is a recognized complication of HIV infection (HIV-related pulmonary arterial hypertension, HRPAH) that is associated with increased mortality [1, 2] . Although right heart catheterization (RHC) is required to definitively diagnose HRPAH, a pulmonary artery systolic pressure (PASP) less than 35 mmHg estimated by Doppler echocardiography is a commonly used cutoff to exclude PAH [3] . Doppler echocardiography estimates of PASP were recently shown to be inaccurate in a general PAH population; however, it is not known whether these findings apply to HIV-infected patients [4, 5] . We evaluated the relationship between Doppler echocardiography PASP and RHC PASP in an HIV-infected cohort.
We invited HIV-infected individuals enrolled in the SCOPE (Study of the Consequences of the Protease Inhibitor Era) cohort at San Francisco General Hospital to undergo Doppler echocardiography. All participants provided written informed consent, and the study was approved by the University of California, San Francisco Committee on Human Research. Doppler echocardiography was performed by a trained sonographer using a GE Vivid 7 system (GE, Milwaukee, Wisconsin, USA). Peak tricuspid regurgitant jet velocity was used to calculate the pressure gradient between the right ventricle and right atrium using the modified Bernoulli equation which was added to right atrial pressure estimated from respiratory variation of the inferior vena cava size to obtain PASP. Because Doppler echocardiography-estimated PASP more than 30 has been associated with increased mortality in patients with sickle cell disease [1] , participants with a Doppler echocardiography-estimated PASP more than 30 mmHg were offered RHC. RHC was performed using a balloon-tipped, flow-directed pulmonary artery catheter and hemodynamic values were obtained using standard methods.
Analyses were performed using the SAS system, version 9.2 (SAS Institute Inc., Cary, North Carolina, USA). The relationship of Doppler echocardiography-estimated PASP with RHC-measured PASP was examined using Spearman's correlation coefficients. The Bland-Altman method was then used to assess the agreement between Doppler echocardiography-estimated and RHCmeasured PASP. Doppler echocardiography-estimated PASP within AE10 mmHg of the value measured on RHC was considered accurate, consistent with the cutoffs used in other recent publications [4] .
Of 422 participants, 129 were found to have PASP more than 30 mmHg on Doppler echocardiography, 76 of whom consented to undergo RHC. Participants who underwent RHC were 80% men, had a median age of 52 years [interquartile range (IQR) 48-56], median duration of HIV infection of 17 years, and 76% were taking antiretroviral therapy. Average PASP estimated on Doppler echocardiography was 35.1 AE 11.5 mmHg and the average PASP measured on RHC was 33.9 AE 12.0 mmHg. Doppler echocardiography PASP was positively correlated with the RHC PASP (r ¼ 0.49, P < 0.0001). Bland-Altman analysis was used to assess the agreement between Doppler echocardiography and RHC PASP (Fig. 1 ). The average bias for Doppler echocardiography PASP was 1.75 mmHg indicating that Doppler echocardiography estimates were on average 1.75 mmHg higher than the RHC measurements; however, the 95% limits of agreement were wide, from À12.0 to 15.5 mmHg. RHC PASP was positively correlated with the difference between the two modalities (Doppler echocardiography PASPÀRHC PASP) suggesting that the bias increased at higher pressures (r ¼ 0.32, P ¼ 0.0048). Overall, Doppler echocardiography estimates of PASP were inaccurate (> AE 10 mmHg different from RHC) in 15 of 76 individuals (19.7%). Fourteen patients received a final diagnosis of PAH. Using the frequently employed threshold of a Doppler echocardiography-estimated PASP greater than or equal to 35 mmHg as abnormal, five in the 14, or over one in three, would have been missed by Doppler echocardiography ( Table 1 ).
The prevalence of PAH in HIV-infected individuals is 1000 times higher than in the general population [1, 2] and is expected to increase [6] . Symptoms of HRPAH are nonspecific so that appropriate testing is often delayed, and diagnosis with advanced, severe disease is common. Sensitive methods are needed to identify patients who require RHC for definitive diagnosis so that treatment may be initiated promptly [7] . In our cohort, Doppler echocardiography PASP was, on average, higher than RHC PASP; however, limits of agreement were wide. At higher values of PASP, Doppler echocardiography was the least accurate and tended to underestimate the RHCmeasured PASP so that PASP less than 35 on Doppler echocardiography did not exclude HRPAH.
Our findings are consistent with other recent reports [4, 5] . In a study comparing Doppler echocardiography and RHC PASP in 65 PAH patients, the bias for the Doppler echocardiography estimates was À0.6 [95% confidence interval (CI) þ38.8 to À40.0] for RHC and Doppler echocardiography was inaccurate in 48% of cases. Although the frequency of under and overestimation of PASP by Doppler echocardiography was equal, the magnitude of underestimation was greater [5] . In another study of 142 patients, despite moderate correlation (r ¼ 0.68, P< 0.001), Doppler echocardiography PASP was inaccurate in 50.6% of patients with a bias of 2.2 mmHg (95% CI À34.3 to 38.6 mmHg) for Doppler echocardiography PASP. Our findings extend upon these other studies, by showing that among individuals with HIV infection, Doppler echocardiography-estimated PASP is not accurate and relying on Doppler echocardiography PASP to exclude a diagnosis of HRPAH could result in missing one of three of patients with HRPAH.
Our study is limited because not all participants consented to undergo RHC and RHC was only performed on participants with a Doppler echocardiography-estimated PASP more than 30 mmHg, so the accuracy of Doppler echocardiography estimates below this value is uncertain. Additionally, the average PASP in our study was low, 33.9 mmHg, compared to a mean PASP of 68.5 and 57 mmHg in other studies, which could affect our assessment of Doppler echocardiography PASP accuracy at higher PASP values. Although we did not perform Doppler echocardiography and RHC simultaneously, they were performed within 1 h of each other and prior reports have confirmed that simultaneous Doppler echocardiography and RHC do not improve Doppler echocardiography estimation of PASP [4] . We did not account for echocardiographic findings such as right heart size, thickness, and function which could modify clinical suspicion for PAH.
Although other Doppler echocardiography findings can raise or reinforce suspicion for PAH, major society guidelines consistently emphasize the importance of noninvasive Doppler echocardiography estimate of PASP in cases of suspected PAH [3, 8] . In this study, we show for the first time in HIV-infected patients at risk for HRPAH that Doppler echocardiography estimates of PASP are not accurate and using a Doppler echocardiography PASP cutoff of more than 35 mmHg may miss patients with HRPAH. Because HRPAH is associated with high mortality and early treatment could improve outcome, timely and accurate diagnosis is critical. RHC should be considered in HIV-infected patients with symptoms [3, 4] . HPTN 052 demonstrated providing antiretroviral treatment to the HIV-positive partner (i.e. using treatment as prevention, TasP) reduces transmission by 96% [3] . Partners PrEP Study demonstrated providing antiretroviral treatment to the HIVnegative partner (i.e. preexposure prophylaxis, PrEP) reduces transmission by 67-75% [4] . Now the efficacy of these interventions has been demonstrated, their feasibility needs to be evaluated. Here we present the first feasibility analysis of implementing public health interventions targeting SDC in sub-Saharan Africa. We assess the feasibility of implementing interventions based on TasP and PrEP.
We used data from 14 countries in sub-Saharan Africa: Burkina Faso, Cameroon, Côte d'Ivoire, Ethiopia, Ghana, Guinea, Kenya, Lesotho, Malawi, Niger, Rwanda, Senegal, Tanzania and Zimbabwe. These countries show considerable variation in epidemic severity; HIV prevalence ranges from 1% (Niger, Senegal) to 24% (Lesotho). Discordancy levels range from 1% (Senegal) to 14% (Lesotho) [5] . Population size (15-49-year olds) ranges from 0.9 million (Lesotho) to 34.5 million (Ethiopia) [6] .
By aggregating data from the 14 countries, we determined whether HIV prevalence and the degree of discordancy are correlated. We then estimated, for each country, the number per 1000 individuals who are HIV-positive (or HIV-negative) and in SDC.
We used data for each country from their Demographic and Health Survey (DHS); these are nationally representative household surveys [7] . Data are collected on HIV prevalence, demographics, and the proportion of couples who are concordant positive (i.e. both individuals are HIV-positive), concordant negative (i.e. both individuals are HIV-negative) or discordant.
We aggregated DHS data from all 14 countries to determine the relationship between HIV prevalence and the level of discordancy; and the level of discordancy and positive concordancy. We then used country-specific DHS data to estimate the number per 1000 individuals who are HIV-positive and in SDC, in concordant couples or single. We made the same estimates for HIVnegative individuals. We used published methods and assumed 70% of the adult population were in couples [8, 9] .
We found [see Figure 1A in Supplementary Material (SM), http://links.lww.com/QAD/A244] an exponential function links HIV prevalence (y) and the level of discordancy (x):
whereâ ¼ 0:13 [95% confidence interval (CI): 0.10-0.17], Â ¼ 4.37 (95% CI: 2.60-7.57), and e is the error term. Consequently, if the prevalence is known for a specific country, the level of discordancy in that country can be estimated using the inverse function of equation (1):
We also found, see Figure 1B in SM, http://links.lww. com/QAD/A244, an exponential function links positive concordancy and discordancy. This is specified by equation (1), but with the parameter values:â ¼ 0:27 (95% CI: 0.22-0.31) and Â ¼ 0.53 (95% CI: 0.28-0.93). It is necessary to know both HIV prevalence and the level of discordancy to determine the feasibility of implementing interventions targeting SDC. However, in many countries, the level of discordancy in couples is unknown.
Here we have identified a relationship between prevalence and discordancy. The statistical model (Equation 1 ) can now be used as a health policy tool to assess the feasibility of implementing interventions targeting SDC in countries where prevalence is known, but the level of discordancy is unknown.
Our findings have significant implications for global health policy. HPTN 052 and the Partners Study have shown TasP and PrEP can be extremely effective in reducing transmission within SDC. Here we have provided the first feasibility study of implementing these interventions. We calculated few (34-48/1000) individuals are HIV-positive (or HIV-negative) and in SDC, even when prevalence is more than 10%. Consequently, whether interventions use TasP or PrEP, they will be very challenging to implement even in high prevalence countries such as Lesotho, Malawi and Zimbabwe. Interventions targeting SDC in Burkina Faso, Côte d'Ivoire, Ethiopia, Ghana, Guinea, Niger, Rwanda and Senegal are unlikely to be feasible, because only 3-19 out of 1000 individuals are HIV-positive and in SDC in these low prevalence (<5%) countries.
In high (>10%) prevalence countries where it may be feasible to implement interventions targeting SDC, their impact on reducing transmission will depend upon the percentage of HIV-positive (for TasP) or HIV-negative (for PrEP) individuals who are in discordant couple. We have calculated that in Lesotho, Malawi and Zimbabwe, 20-27% of all HIV-positive, but less than 6% of all HIVnegative individuals, are in SDC. Consequently, using TasP for HIV-positive partners in these countries (if coverage is high [9] ) could potentially significantly reduce transmission. However, providing PrEP to HIV-negative partners may have little impact on reducing transmission.
